Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest.
Treatment of brain injury following circulatory arrest is a challenging health issue with no viable therapeutic options. Based on studies in a clinically relevant large animal (canine) model of hypothermic circulatory arrest (HCA)-induced brain injury, neuroinflammation and excitotoxicity have been identified as key players in mediating the brain injury after HCA. Therapy with large doses of valproic acid (VPA) showed some neuroprotection but was associated with adverse side effects. For the first time in a large animal model, we explored whether systemically administered polyamidoamine (PAMAM) dendrimers could be effective in reaching target cells in the brain and deliver therapeutics. We showed that, upon systemic administration, hydroxyl-terminated PAMAM dendrimers are taken up in the brain of injured animals and selectively localize in the injured neurons and microglia in the brain. The biodistribution in other major organs was similar to that seen in small animal models. We studied systemic dendrimer-drug combination therapy with two clinically approved drugs, N-acetyl cysteine (NAC) (attenuating neuroinflammation) and valproic acid (attenuating excitotoxicity), building on positive outcomes in a rabbit model of perinatal brain injury. We prepared and characterized dendrimer-NAC (D-NAC) and dendrimer-VPA (D-VPA) conjugates in multigram quantities. A glutathione-sensitive linker to enable for fast intracellular release. In preliminary efficacy studies, combination therapy with D-NAC and D-VPA showed promise in this large animal model, producing 24 h neurological deficit score improvements comparable to high dose combination therapy with VPA and NAC, or free VPA, but at one-tenth the dose, while significantly reducing the adverse side effects. Since adverse side effects of drugs are exaggerated in HCA, the reduced side effects with dendrimer conjugates and suggestions of neuroprotection offer promise for these nanoscale drug delivery systems.
Center for Nanomedicine/Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins School of Medicine , Baltimore, Maryland 21287, United States.
Manoj K
MK
Mishra
Claude A
CA
Beaty
Wojciech G
WG
Lesniak
Siva P
SP
Kambhampati
Fan
F
Zhang
Mary A
MA
Wilson
Mary E
ME
Blue
Juan C
JC
Troncoso
Sujatha
S
Kannan
Michael V
MV
Johnston
William A
WA
Baumgartner
Rangaramanujam M
RM
Kannan
D000111:Acetylcysteine / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001692:Biological Transport; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D001930:Brain Injuries / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D050792:Circulatory Arrest, Deep Hypothermia Induced / Q000009:adverse effects*; D050091:Dendrimers / Q000737:chemistry / Q000378:metabolism*; D004195:Disease Models, Animal; D004285:Dogs; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000378:metabolism; D050997:Nanomedicine; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D016896:Treatment Outcome; D014635:Valproic Acid / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D050091:Dendrimers; D004337:Drug Carriers; C104700:PAMAM Starburst; D014635:Valproic Acid; D000111:Acetylcysteine